PI3K/Akt/mTOR信号通路及其相关基因突变与子宫内膜癌靶向性药物治疗的研究进展  

Research advances of PI3K/Akt/mTOR signaling pathway with its related gene mutations and the targeted therapy for endometrial cancer

作　　者：曹楚楚 黄炉仁 傅芬[1] 

机构地区：[1]南昌大学第二附属医院妇产科,江西南昌330006

出　　处：《基础医学与临床》2017年第1期118-122,共5页Basic and Clinical Medicine

基　　金：江西省科技计划(20132BAB205001)

摘　　要：子宫内膜癌(EC)是最常见的女性生殖道恶性肿瘤之一,其发生发展的分子生物学机制十分复杂。近年来研究发现,磷脂酰肌醇-3激酶/蛋白激酶B/哺乳动物雷帕霉素靶蛋白(PI3K/Akt/mTOR)信号通路调节异常与子宫内膜癌密切相关。PI3K/Akt/mTOR信号通路中的多种受体及激酶的突变和异常激活,可能成为子宫内膜癌治疗的靶点。Endometrial cancer（ EC） is one of the most common gynecological cancer,of which the molecular biological mechanisms is very complex. In recent years,it has been reported that the abnormally regulated PI3 K / Akt /mTOR signaling pathway is significantly related with endometrial cancer. The mutation and abnormal activation of the receptors and kinase of the PI3 K / Akt / mTOR signaling pathway is a potential therapeutic target of endometrial cancer.

关 键 词：PI3K/Akt/mTOR信号通路 基因突变 子宫内膜癌 靶向治疗 

分 类 号：R737.33[医药卫生—肿瘤]